Notice2022-00887
Uniform Formulary Beneficiary Advisory Panel; Notice of Federal Advisory Committee Meeting
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
January 19, 2022
Issuing agencies
Defense Department
Abstract
The DoD is publishing this notice to announce that the following Federal Advisory Committee meeting of the Uniform Formulary Beneficiary Advisory Panel (UFBAP) will take place.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 12 (Wednesday, January 19, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 12 (Wednesday, January 19, 2022)]
[Notices]
[Pages 2767-2768]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-00887]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF DEFENSE
Office of the Secretary
Uniform Formulary Beneficiary Advisory Panel; Notice of Federal
Advisory Committee Meeting
AGENCY: Under Secretary of Defense for Personnel and Readiness,
Department of Defense (DoD).
ACTION: Notice of Federal Advisory Committee meeting.
-----------------------------------------------------------------------
SUMMARY: The DoD is publishing this notice to announce that the
following Federal Advisory Committee meeting of the Uniform Formulary
Beneficiary Advisory Panel (UFBAP) will take place.
DATES: Open to the public on day 1 of the meeting Tuesday, January 25,
2022, 10:00 a.m.-6:00 p.m. and on Day 2 of the meeting January 26,
2022, 9:00 a.m.-6:00 p.m. (Eastern Standard Time).
ADDRESSES: The meeting will be held telephonically or via conference
call. The phone number for the remote access on January 25-26, 2022 is:
CONUS: 1-888-946-3815; OCONUS: 1-415-228-4881; PARTICIPANT CODE:
6978956.
These numbers and the dial-in instructions will also be posted on
the Uniform Formulary Beneficiary Advisory Panel website at: <a href="https://www.health.mil/About-MHS/OASDHA/Defense-Health-Agency/Operations/Pharmacy-Division/Beneficiary-Advisory-Panel">https://www.health.mil/About-MHS/OASDHA/Defense-Health-Agency/Operations/Pharmacy-Division/Beneficiary-Advisory-Panel</a>.
FOR FURTHER INFORMATION CONTACT: Colonel Paul J. Hoerner, USAF, 703-
681-2890 (Voice), <a href="/cdn-cgi/l/email-protection#bedad6df90d0ddcc90d4938890d3dcc690dcdfceccdbcfcbdbcdcacdfed3dfd7d290d3d7d2"><span class="__cf_email__" data-cfemail="86e2eee7a8e8e5f4a8ecabb0a8ebe4fea8e4e7f6f4e3f7f3e3f5f2f5c6ebe7efeaa8ebefea">[email protected]</span></a> (Email). Mailing
address is 7700 Arlington Boulevard, Suite 5101, Falls Church, VA
22042-5101. Website: <a href="https://www.health.mil/About-MHS/OASDHA/Defense-Health-Agency/Operations/Pharmacy-Division/Beneficiary-Advisory-Panel">https://www.health.mil/About-MHS/OASDHA/Defense-Health-Agency/Operations/Pharmacy-Division/Beneficiary-Advisory-Panel</a>.
The most up-to-date changes to the meeting agenda can be found on the
website.
SUPPLEMENTARY INFORMATION: Due to circumstances beyond the control of
the Department of Defense and the Designated Federal Officer, the UFBAP
was unable to provide public notification required by 41 CFR 102-
3.150(a) concerning its January 25 through 26, 2022 meeting.
Accordingly, the Advisory Committee Management Officer for the
Department of Defense, pursuant to 41 CFR 102-3.150(b), waives the 15-
calendar day notification requirement. This meeting is being held under
the provisions of the Federal Advisory Committee Act (FACA) (5 U.S.C.,
Appendix) and 41 CFR 102-3.140 and 102-3.150. The Panel will review and
comment on recommendations made to the Director, Defense Health Agency,
by the Pharmacy and Therapeutics Committee, regarding the Uniform
Formulary.
Purpose of the Meeting: The DoD is publishing this notice to
announce that the following Federal Advisory Committee meeting of the
Uniform Formulary Beneficiary Advisory Panel will take place.
Agenda Items
1. Day 1--January 25, 2022
a. 10:00 a.m.-10:10 a.m. Sign In for UFBAP members
b. 10:10 a.m.-10:20 a.m. Welcome and Opening Remarks by Col Paul J.
Hoerner, Designated Federal Officer (DFO), UFBAP
c. 10:20 a.m.-10:30 a.m. Introduction of UFBAP Members by Col Hoerner
d. 10:30 a.m.-10:45 a.m. Opening Remarks by UFBAP Co-Chair Senior Chief
Petty Officer (Ret) Jon R. Ostrowski, Non-Commissioned Officers
Association
e. 10:45 a.m.-11:00 a.m. Introductory Remarks by CDR Scott Raisor,
Interim Chief, Formulary Management Branch
2. Discussion of the February 2021 DoD P&T Committee Recommendations
Scheduled Therapeutic Class Reviews
a. 11:00 a.m.-11:30 a.m. Breast Cancer Agents: Cyclin Dependent Kinase
Inhibitors (LCDR Todd Hansen)
b. 11:30 a.m.-12:00 p.m. Pulmonary III Agents (Dr. Angela Allerman)
c. 12:00 p.m.-1:00 p.m. Break for Lunch
d. 1:00 p.m.-1:45 p.m. Newly Approved Drugs Review (Dr. Amy Lugo, and
other FMB staff, including CDR Raisor, and MAJ Adam Davies)
e. 1:45 p.m.-2:45 p.m. Pertinent Utilization Management Issues (MAJ
Davies, and other FMB staff, including Dr. Allerman, and CDR Raisor)
* Note that the UFBAP Discussion and Vote will follow each section
f. 2:45 p.m.-3:00 p.m. Break
[[Page 2768]]
3. Discussion of the May 2021 DoD P&T Committee Recommendations
Scheduled Therapeutic Class Reviews
a. 3:00 p.m.-3:30 p.m. Menopausal Hormone Therapy: Single Agents,
Combination Agents, and Vaginal Agents (LCDR Elizabeth Hall)
b. 3:30 p.m.-4:00 p.m. Sleep Disorders: Insomnia (Dr. Lugo)
c. 4:00 p.m.-4:45 p.m. Newly Approved Drugs Review (Dr. Lugo, and other
FMB staff including, LCDR Hall, MAJ Davies, LCDR Hansen, and Dr.
Allerman)
d. 4:45 p.m.-5:15 p.m. Pertinent Utilization Management Issues (MAJ
Davies and other FMB staff including Dr. Allerman, Dr. Lugo, and LCDR
Hall)
e. 5:15 p.m.-5:30 p.m. Re-evaluation of Nonformulary generics (Dr.
Allerman)
* Note that the UFBAP Discussion and Vote will follow each section
f. 5:30 p.m.-5:45 p.m. Closing Remarks by Senior Chief Petty Officer
(Ret) Ostrowski
g. 5:45 p.m.-6:00 p.m. Closing Remarks by Col Hoerner
Agenda Items
1. Day 2--January 26, 2022
a. 9:00 a.m.-9:10 a.m. Sign In for UFBAP members
b. 9:10 a.m.-9:15 a.m. Welcome and Opening Remarks by Col Hoerner
c. 9:15 a.m.-9:30 a.m. Opening Remarks by Senior Chief Petty Officer
(Ret) Ostrowski
2. Discussion of the August 2021 DoD P&T Committee Recommendations
Scheduled Therapeutic Class Reviews
a. 9:30 a.m.-10:00 a.m. Leukemia and Lymphoma Agents, Burton Tyrosine
Kinase Inhibitors LCDR Hansen)
b. 10:00 a.m.-10:30 a.m. Laxative-Cathartics-Stool Softeners--Bowel
Preparations (Dr. Lugo)
c. 10:30 a.m.-10:45 a.m. Break
d. 10:45 a.m.-11:45 a.m. Newly Approved Drugs Review (Dr. Lugo and
other FMB staff, including LCDR Hall, LCDR Hansen, Dr. Allerman, CDR
Raisor, and MAJ Davies)
e. 11:45 a.m.-12:45 p.m. Pertinent Utilization Management Issues (MAJ
Davies and other FMB staff, including Dr. Lugo, and CDR Raisor)
f. 12:45 p.m.-1:00 p.m. Tier Co-Payment Change for the Pulmonary III
Agents (CDR Raisor)
g. 1:00 p.m.-1:15 p.m. Brand over Generic Authorization and Tier 1 Co-
Payment Change for the Pulmonary Arterial Hypertension Drugs (Dr.
Allerman)
* Note that the UFBAP Discussion and Vote will follow each section
h. 1:15 p.m.-2:15 p.m. Break for Lunch
3. Discussion of the November 2021 DoD P&T Committee Recommendations
Scheduled Therapeutic Class Reviews
a. 2:15 p.m.-3:00 p.m. Continuous Glucose Monitoring Systems--
Therapeutic Agents (Dr. Lugo)
b. 3:00 p.m.-3:30 p.m. Immunological Agents Miscellaneous--Subcutaneous
Immunoglobulins (LCDR Hansen)
c. 3:30 p.m.-4:30 p.m. Newly Approved Drugs Review (Dr. Lugo and other
FMB staff including LCDR Hansen, LCDR Giao Phung, LCDR Hall, MAJ Davies
and Maj Angelina Escano)
d. 4:30 p.m.-4:45 p.m. Break
e. 4:45 p.m.-5:45 p.m. Pertinent Utilization Management Issues (MAJ
Davies)
*Note that the UFBAP Discussion and Vote will follow each section
f. 5:45 p.m.-5:55 p.m. Closing Remarks by Senior Chief Petty Officer
(Ret) Ostrowski
g. 5:55 p.m.-6:00 p.m. Closing Remarks by Col Hoerner
Meeting Accessibility: Pursuant to section 10(a)(1) of the FACA and
41 CFR 102-3.140 through 102-3.165, and subject to the availability of
phone lines, this meeting is open to the public. Telephone lines are
limited and available to the first 220 people dialing in. There will be
220 line total: 200 domestic and 20 international, including leader
lines.
Written Statements: Pursuant to 41 CFR 102-3.10, and section
10(a)(3) of FACA, interested persons or organizations may submit
written statements to the Uniform Formulary Beneficiary Advisory Panel
about its mission and/or the agenda to be addressed in this public
meeting. Written statements should be submitted to the Uniform
Formulary Beneficiary Advisory Panel's Designated Federal Officer
(DFO). The DFO's contact information can be found in the FOR FURTHER
INFORMATION CONTACT section of this notice. Written comments or
statements must be received by the Uniform Formulary Beneficiary
Advisory Panel's DFO at least two (2) calendar days prior to the
meeting so they may be made available to the Uniform Formulary
Beneficiary Advisory Panel for its consideration prior to the meeting.
The DFO will review all submitted written statements and provide copies
to all Uniform Formulary Beneficiary Advisory Panel members.
Dated: January 12, 2022.
Aaron T. Siegel,
Alternate OSD Federal Register, Liaison Officer, Department of Defense.
[FR Doc. 2022-00887 Filed 1-18-22; 8:45 am]
BILLING CODE 5001-06-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on January 19, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.